These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26084808)

  • 1. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.
    Flaherty KT; Hamilton BK; Rosen MA; Amaravadi RK; Schuchter LM; Gallagher M; Chen H; Sehgal C; O'Dwyer PJ
    Oncologist; 2015 Aug; 20(8):952-9. PubMed ID: 26084808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
    Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
    Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM
    Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
    Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
    Reilley MJ; Bailey A; Subbiah V; Janku F; Naing A; Falchook G; Karp D; Piha-Paul S; Tsimberidou A; Fu S; Lim J; Bean S; Bass A; Montez S; Vence L; Sharma P; Allison J; Meric-Bernstam F; Hong DS
    J Immunother Cancer; 2017; 5():35. PubMed ID: 28428884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK; Hwang J; Magbanua MJ; Watt L; Beumer JH; Christner SM; Baruchel S; Wu B; Fong L; Yeh BM; Moore AP; Ko AH; Korn WM; Rajpal S; Park JW; Tempero MA; Venook AP; Bergsland EK
    Br J Cancer; 2013 Oct; 109(7):1725-34. PubMed ID: 24022191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
    Grignol VP; Olencki T; Relekar K; Taylor C; Kibler A; Kefauver C; Wei L; Walker MJ; Chen HX; Kendra K; Carson WE
    J Immunother; 2011; 34(6):509-15. PubMed ID: 21654521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
    Yardley DA; Burris HA; Markus T; Spigel DR; Greco FA; Mainwaring M; Waterhouse DM; Webb CD; Hainsworth JD
    Clin Breast Cancer; 2009 Nov; 9(4):237-42. PubMed ID: 19933079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
    Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
    Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib in advanced chordoma: A retrospective case series analysis.
    Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
    Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
    Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
    Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
    Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
    Hirai I; Tanese K; Fukuda K; Fusumae T; Nakamura Y; Sato Y; Amagai M; Funakoshi T
    Medicine (Baltimore); 2021 Dec; 100(49):e27832. PubMed ID: 34889232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.